# In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

> **NCT04616248** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Southern California** · enrollment: 14 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8
- Unresectable Breast Carcinoma
- Metastatic Melanoma
- Unresectable Melanoma
- Cutaneous Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Soft Tissue Sarcoma
- Bone Sarcoma
- Sarcoma,Soft Tissue
- Sarcoma of Bone
- Basal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- **DRUG:** Poly ICLC
- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Recombinant Flt3 Ligand
- **DRUG:** Pembrolizumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04616248
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-09
- **Primary completion:** 2027-01-09
- **Final completion:** 2028-01-09
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04616248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04616248, "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04616248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*